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Praziquantel for the treatment of schistosomiasis during human 
pregnancy
Jennifer F Friedman,a Remigio M Olveda,b Mark H Mirochnick,c Amaya L Bustinduyd & Alison M Elliottd
Introduction
In 2014, over 230 million individuals, including 40 million 
women of reproductive age, were estimated to be infected with 
Schistosoma haematobium, S. japonicum and/or S. mansoni.1 
Despite the widespread availability of effective, praziquantel-
based treatment, schistosomiasis remains the cause of sub-
stantial morbidity and mortality in many low- and middle-
income countries.2 In a meta-analysis of the disability-related 
outcomes of endemic schistosomiasis, the disability weight 
assigned to schistosomiasis – which was based on the disease’s 
impact on a range of functional domains, ranged between 2% 
and 15%.3 The most recent Global Burden of Disease estimates, 
from 1980–2016, indicate that approximately 10 000 schistoso-
miasis-related deaths occur each year.4 Among non-pregnant 
subjects, schistosomiasis has been implicated as a contributor 
to undernutrition5–11, probably via the suppression of appetite12 
and to inflammation-mediated cachexia.13 Schistosomiasis also 
contributes to the global burden of anaemia7,9,14,15 Individuals 
with heavy infections may lose so much blood in their stools 
and/or urine that they develop iron-deficiency anaemia.16–19 
Pregnant women may experience any of these morbidities and 
others, e.g. hepatic fibrosis and the associated increased risk of 
oesophageal varices, at approximately the same rates as seen 
among non-pregnant individuals.3
Both S. haematobium20 and S. mansoni21 are known to 
contribute to the burden of anaemia in pregnancy, particularly 
at higher intensities of infection. The same may be true for S. 
japonicum. For example, in a recently completed randomized 
controlled trial in the Philippines, praziquantel given as a 
total dose of 60 mg per kg, to S. japonicum-infected pregnant 
women at 12–16 weeks’ gestation, led to improved maternal 
ferritin and a trend towards increased neonatal iron endow-
ment.22
In 2000, urogenital schistosomiasis, which is largely 
caused by S. haematobium, was considered endemic in 53 
countries in Africa and the Middle East.23 In areas where S. 
haematobium is endemic, women of reproductive age may 
experience chronic female genital schistosomiasis and this 
may place the women at increased risk of the acquisition and 
transmission of human immunodeficiency virus (HIV).24,25
Praziquantel was released in 1979, but the United States 
Food and Drug Administration (FDA) still places it in preg-
nancy class B26, indicating that animal reproduction studies27,28 
have failed to demonstrate a risk to the fetus but no adequate 
and well-controlled studies in pregnant women have been 
conducted. In 2002, the World Health Organization (WHO) 
sponsored an informal consultation on the use of praziquantel 
during pregnancy and lactation. The report from that consulta-
tion, published in 2003, recommended that all schistosome-
infected pregnant and breastfeeding women be considered 
high-risk groups and be offered treatment with praziquantel 
either individually or during treatment campaigns.29–31
Given the evidence of praziquantel’s safety in animal 
models, encouraging post-market surveillance data and its 
successful use in the treatment of neurocysticercosis during 
pregnancy, a similar recommendation was made in 2006, as 
part of WHO’s Guidelines for Preventative Chemotherapy for 
Helminthiasis.2 These guidelines recommended that pregnant 
and breastfeeding women be included in mass administrations 
of praziquantel, but also noted the need for randomized con-
trolled trials to assess praziquantel’s safety and efficacy when 
given to such women. Initially, the lack of sufficient safety 
data from controlled trials made many countries reluctant to 
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follow this recommendation. Since 2006, 
however, there have been two relevant 
randomized controlled trials22,32 and the 
results of those trials have prompted 
some more countries, but not all, to 
follow the guidelines’ recommendations 
on praziquantel use.33 In Zanzibar, in 
the United Republic of Tanzania, where 
local guidelines do not recommend 
treatment of pregnant women, two of the 
most commonly cited reasons for not re-
ceiving praziquantel during community 
treatment campaigns were pregnancy 
and breastfeeding.34 China,35 Gabon,36 
Kenya37 and Uganda38 have still to adopt 
policies to treat schistosome infections 
in pregnant women. Even in countries 
where the relevant national policy has 
been changed to include pregnant and 
breastfeeding women in mass admin-
istrations of praziquantel, some such 
women are still being excluded, because 
schistosomiasis programme managers 
and health-care providers remain un-
aware of the change. Millions of women 
of reproductive age may miss treatment 
for many years during repeated cycles of 
pregnancy and lactation.
Below, we review safety data from 
non-interventional human studies and 
summarize the data addressing safety, 
efficacy and pharmacokinetics from 
the relevant post-2006 randomized 
controlled trials.22,32 We identify current 
barriers to the treatment of pregnant 
women with praziquantel, in those 
countries where such treatment is al-
ready national policy and discuss ways 
in which these barriers may be over-
come. Given the relevant data published 
since 2006, we recommend the inclusion 




Over more than 30 years of post-market 
experience with praziquantel, no reports 
of serious adverse events relevant to 
human pregnancy have been published, 
e.g. abortions, stillbirths or congenital 
anomalies. In a retrospective study in 
Sudan, 88 pregnancies in which there 
had been inadvertent praziquantel expo-
sure, including 37 with exposure in the 
first trimester, were compared with 549 
other pregnancies in which there had 
been no praziquantel exposure.39 None 
of the 88 exposed pregnancies ended in 
abortion or stillbirth and no congenital 
anomalies were noted by clinical exami-
nation of the babies born to the exposed 
women, or to the unexposed. In a small 
case series of travel-related acquisi-
tion of schistosomiasis, four pregnant 
women were treated with 60 mg pra-
ziquantel per kg, including two treated 
during the first trimester.40 Treatment 
did not culminate in any serious adverse 
events for the mothers or neonates. In a 
prospective study conducted in Sudan, 
25 pregnant Sudanese women with S. 
mansoni infections were treated with 
a single dose of praziquantel, at 40 mg 
per kg, during different trimesters. Al-
though one of these women experienced 
a spontaneous abortion at 10 weeks’ ges-
tation and three weeks post-treatment, 
the frequency of abortion among the 
treated women was similar to the back-
ground rate in the study community.41 
In the treatment of neurocysticercosis, 
pregnant women have been given daily 
doses of praziquantel for up to 21 days 
with no apparent adverse events.42
Post-2006 trials
Two randomized, double-blind, pla-
cebo-controlled trials22,32 have been 
completed since WHO’s publication of 
its last, i.e. 2006, guidelines addressing 
the treatment of pregnant women with 
praziquantel.2 
Uganda
In Uganda, where S. mansoni is endemic, 
women attending a hospital-based 
antenatal clinic were assigned into one 
of four treatment groups: placebo plus 
placebo, albendazole plus placebo, pra-
ziquantel plus placebo or albendazole 
plus praziquantel.32 As women who did 
not have schistosomiasis were included 
in the randomized sample, the study 
mimicked a typical mass drug admin-
istration in which infection status is 
not known at the time of treatment. 
Each single treatment was given during 
the second or third trimester, at a mean 
gestational age of 26.6 weeks. This large 
trial, which included 2507 women in its 
baseline analysis, found that praziquan-
tel had no significant effect on maternal 
anaemia or birth weight, even among the 
women who were each confirmed to be 
infected with S. mansoni by the exami-
nation of a single stool sample. Perinatal 
mortality and congenital anomalies were 
as common in the placebo plus placebo 
group as in any of the other groups. 
Although, the infants born to mothers 
who had been given albendazole or pra-
ziquantel when pregnant, and infected 
with S. mansoni, showed a relatively 
high risk of infantile eczema,43 this did 
not translate into an increased risk of 
asthma in adolescence.44
Philippines
In Leyte in the Philippines, women who 
were infected with S. japonicum were 
recruited for another randomized con-
trolled trial.22 Overall, 360 women were 
treated, at 12–16 weeks’ gestation, either 
with praziquantel, given as two doses, 
each of 30 mg per kg, with a four-hour 
interval, or with a placebo. Praziqu-
antel treatment was found to have no 
significant impact on birth weight, i.e. 
the primary outcome, or on secondary 
outcomes such as the prevalences of 
low birth weight, intrauterine growth 
restriction and prematurity. Analysis 
of cytokine profiles indicated that such 
treatment also had no detectable effect 
on maternal inflammation, even by 
32 weeks’ gestation. The treatment of 
schistosomiasis has complex effects on 
the immune system, including release 
of adult-worm antigens, enhanced re-
sponses to these antigens and a decline 
in immunoregulatory activity.45,46 At 
32 weeks’ gestation, pregnant women 
have been found to have significantly 
higher blood concentrations of tumour 
necrosis factor-α when infected with S. 
japonicum than when uninfected, with 
mean values of 2.11 and 0.34 pg per mL, 
respectively.47 In the trial in Leyte, the 
corresponding concentrations, again 
at 32 weeks’ gestation, were 1.6 pg per 
mL for the placebo group and 1.3 pg 
per mL for the praziquantel group.22 
These results indicate that, in the trial, 
praziquantel treatment did not resolve 
inflammation in the ensuing five or 
six months. The lack of a significant 
impact of praziquantel on birth weight 
may also be a reflection of the generally 
light infections; only 9.7% of the women 
enrolled in the trial had moderate or 
intense S. japonicum infections.
In the trial in Leyte, all of the preg-
nant women given praziquantel showed 
parasitological cure at 22 weeks’ gesta-
tion.22 Praziquantel treatment culminat-
ed in increased maternal serum ferritin 
levels at 32 weeks’ gestation as well as a 
trend towards improved neonatal iron 
endowment. Such treatment was not 
found to have any significant impact on 
maternal haemoglobin or anaemia risk 
during the trial. However, significant 
improvements in haemoglobin may 
take more than three months to show 
Bull World Health Organ 2018;96:59–65| doi: http://dx.doi.org/10.2471/BLT.17.198879 61
Policy & practice
Praziquantel and human pregnancyJennifer F Friedman et al.
after praziquantel treatment5 and the 
low prevalence of maternal anaemia and 
the generally low intensity of the S. ja-
ponicum infections in the trial may have 
masked any potentially beneficial effects 
of praziquantel on maternal anaemia. 
Praziquantel treatment was well toler-
ated in the trial and the reactogenicity 
rates in the treated pregnant women 
were similar to those observed in treated 
non-pregnant participants. Importantly, 
such treatment had no significant effect 
on key safety outcomes such as abortion, 
congenital anomalies and intrauterine 
fetal death.48
Pharmacokinetics
Praziquantel pharmacokinetics in non-
pregnant adults are characterized by 
peak concentrations one to three hours 
after a dose and a terminal half-life 
that ranges between 0.8 and 1.5 hours. 
During pregnancy, however, important 
physiological changes could affect drug 
pharmacokinetics. For example, there 
is a decrease in gastric emptying, de-
creased bioavailability, decreased drug 
binding, altered liver metabolism and 
increased elimination.49 The pregnancy-
related changes that occur in pharma-
cokinetic distribution and exposure 
parameters include decreased peak 
plasma concentrations, longer elimina-
tion half-lives and a reduction in the so-
called area under the curve, which leads 
to lower levels of drug exposure.50 The 
appropriate drug dose and regimen to be 
given during gestation must therefore be 
carefully determined.
The first detailed study of the phar-
macokinetics of praziquantel in preg-
nant women was conducted as part of 
the randomized controlled trial in Leyte. 
The results of this study, which included 
assays quantifying the concentrations 
of praziquantel in the milk of treated 
women have yet to be published. A 
preliminary analysis indicated that the 
pharmacokinetics of praziquantel in 
women in early pregnancy, women in 
late pregnancy and postpartum subjects 
were similar (M Mirochnick, Depart-
ment of Pediatrics, Boston University 
School of Medicine, unpublished data, 
2017). For example, the corresponding 
mean areas under the curve were found 
to be 8.9 mg-hour per L for women in 
early pregnancy, 15.0 for women in late 
pregnancy and 13.1 for postpartum 
subjects. Drawing conclusions from 
such data are difficult as there has only 
been one previous study of the pharma-
cokinetics of praziquantel in a study area 
with endemic S. japonicum, and that 
was confined to just two non-pregnant 
women.51 The results of the ongoing 
pharmacodynamic analysis from the 
Leyte trial, will hopefully help clarify the 
optimal dosing of praziquantel during 
pregnancy.
Policy implications
Since 2006, when WHO last published a 
recommendation on the use of praziqu-
antel in pregnant and breastfeeding wom-
en, considerable relevant information has 
been published or, at least, analysed. This 
information, from two randomized con-
trolled trials and additional observational 
and pharmacokinetic studies, provides 
support for WHO’s recommendation. 
In the trials, no increased risk of adverse 
pregnancy or neonatal outcomes was 
observed when praziquantel was given 
either at 40 mg per kg during the second 
or third trimester or at a total dose of 
60 mg per kg at 12–16 weeks’ gestation. 
Given this improved evidence of the 
drug’s safety, we recommend that preg-
nant and breastfeeding women now be 
included in all praziquantel-based mass 
drug administrations.
Policies for the treatment of preg-
nant women with praziquantel must 
consider the timing of such treatment. 
The safety of giving praziquantel to preg-
nant women during the first trimester 
has not been well assessed. However, the 
apparent lack of teratogenic effects in 
mice, rats or rabbits given praziquantel 
while pregnant indicates that the drug 
may be safe to use during the classic 
teratogenic period of the human first 
trimester.28,52 The observations made, 
retrospectively, on women inadvertently 
exposed to praziquantel during the 
first trimester,39 case reports of treat-
ment during the first trimester with no 
untoward effects40 and the encouraging 
results of over 30 years of post-market 
surveillance involving many millions of 
doses provide additional reassurance. 
Given the lack of data suggesting that 
praziquantel poses a risk to mothers 
or fetuses and the costs and logistical 
barriers of pregnancy testing, we do not 
advocate that routine pregnancy testing 
of women of reproductive age forms a 
part of any campaign of praziquantel-
based mass drug administrations.
The possibility of treating pregnant 
women outside of mass drug adminis-
trations needs to be considered. Based 
on the demonstrated safety of praziqu-
antel during the second and third tri-
mesters, we recommend the treatment 
of pregnant women during routine visits 
for antenatal care if the women request 
such treatment or show the symptoms 
of schistosomiasis. We refrain from 
recommending that all pregnant women 
in areas with endemic schistosomiasis 
be treated with praziquantel as part of 
a routine package of antenatal care, at 
least until there has been a more de-
tailed analysis of the potential costs and 
benefits. In the Ugandan randomized 
controlled trial, such an approach, in 
which all women were treated regardless 
of their infection status, did not reduce 
maternal anaemia status or increase 
birth weights significantly.32
Finally, provision of praziquantel 
for non-pregnant women of reproduc-
tive age, either as an individualized 
treatment or part of a mass drug ad-
ministration, is important for women’s 
own health and well-being. If oppor-
tunities for such treatment are missed, 
women are placed at increased risk 
of chronic morbidity and the intense 
schistosome infections that are par-
ticularly associated with anaemia and 
undernutrition.1,3,5,6,14,15 If left untreated, 
women living in areas endemic for S. 
haematobium face developing female 
genital schistosomiasis which may, in 
turn, increase the risks of acquiring and 
transmitting HIV.25,53
Barriers to policy adoption
Although recent progress in many rel-
evant areas should increase the access 
of pregnant women to praziquantel 
treatment, barriers to adopting polices 
for such treatment still remain. The rel-
evant information collected since 2006 
should provide reassurance to countries 
that have not yet adopted WHO’s recom-
mendation on the treatment of pregnant 
and breastfeeding women with the 
drug. By creating this update, we hope 
to mitigate any remaining concerns of 
policy-makers. 
Since the expiration of Bayer’s pat-
ent in 1994, the price of praziquantel, 
which was once a substantial barrier to 
the drug’s widespread use, has plum-
meted, to approximately 0.08 United 
States dollar (US$) per 600-mg tablet or 
approximately US$ 0.20–0.30 per treat-
ment course in 2017.54 Furthermore, in 
recent years, the supply of praziquantel 
has increased dramatically. In 2016, to 
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meet the need for treatment, Merck 
Soreno pledged to donate 250 million 
tablets of praziquantel annually.55 Pra-
ziquantel is also now available from 
the United Kingdom of Great Britain 
and Northern Ireland’s Department for 
International Development, the United 
States Agency for International Devel-
opment, the World Bank and World Vi-
sion, such that sufficient supply should 
be available to provide close to 130 
million treatments annually.55 
Finally, even among countries 
that have adopted policies to include 
pregnant and breastfeeding women in 
praziquantel-based mass drug admin-
istrations, substantial gaps still exist in 
the implementation of those policies. 
One issue is the prioritization of school-
based or community-based mass drug 
administrations in some areas. School-
based programmes risk missing most 
women of reproductive age, as well as 
adolescent girls who cannot afford to at-
tend school, especially if the schools in-
volved are primary. Many programmes 
for the support of mass drug administra-
tions are so poorly staffed and resourced 
that treatments cannot be delivered at 
the intervals indicated by the commu-
nity prevalence of schistosome infection. 
Community health workers need to be 
resourced better and educated on the 
safety of praziquantel for pregnant and 
breastfeeding women.
In a collaboration with regulatory 
staff at the FDA and United States  Na-
tional Institutes of Health, we began 
work to change the Food and Drug Ad-
ministration’s pregnancy designation for 
praziquantel, from class B to class A. In 
2015, however, FDA moved away from 
the letter categories for pregnancy desig-
nations, to a more narrative approach.56
Conclusion
Based on recent evidence of the safety 
of praziquantel in human pregnancy, we 
recommend that, in areas with endemic 
schistosomiasis, women of reproductive 
age, including pregnant and breastfeed-
ing women, be treated with praziquantel 
either individually, in local antenatal 
clinics, or in mass drug administrations. 
As more women are treated, surveil-
lance to identify any untoward effects 
of treatment should be continued. It is 
expected that treatment may improve 
both maternal and neonatal iron stores.22 
Surprisingly, two randomized controlled 
trials did not reveal an impact of the 
treatment of pregnant women with pra-
ziquantel on subsequent birth weights. 
According to data from animal models 
and observational and mechanistic 
studies on humans, however, it remains 
possible that, although schistosomiasis 
adversely affects pregnancy outcomes, 
treatment during gestation is too late 
to impact birth outcomes during that 
pregnancy. Individualized treatment 
during antenatal care and treatment in 
mass drug administrations may, how-
ever, increase the likelihood that women 
enter subsequent pregnancies free of 
infection. Regular treatment is likely 
to impact both the overall prevalence 
of infection and the prevalence of the 
intense infections that are most closely 
associated with maternal morbidity. ■
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صخلم
شربلا ىدل لملحا ةترف للاخ ايسراهلبلا ءاد جلاعل “ ليتناوكيزابرلا“ ءاود مادختسا
 ـب  ردقُي  باجنلإا نس في ءاسنلا  نم ددع ةباصإ 2014  ماع دهش
 ايسراهلبلا  وأ/و  ،ةيومدلا  ايسراهلبلا  ىودعب  ةأرما  نويلم 40
 ةحصلا  ةمظنم  تصوأو  .ةينوسنلما  ايسراهلبلا  وأ/و  ،ةينابايلا
 ءاودب  جلاعلا  ميدقتب  2006  ماعو 2003  ماع نم لك في ةيلماعلا
 ةعاضر  نعضري  تيلالاو  لماولحا  ءاسنلا  عيملج  ”ليتناوكيزابرلا“
 جلاعلا ميدقت ناك ءاوس ،ايسراهلبلا ىودعب تاباصلما نم ةيعيبط
 ةمظنم اًضيأ تحصرو .ةيجلاع ةلحم للاخ نم وأ يدرف ساسأ لىع
 ةاشعم براتج ءارجلإ ةجاح دوجوب 2006 ماع في ةيلماعلا ةحصلا
 هيرثأتو جلاعلا نم عونلا اذه ةيلاعف ىدم مييقتل دهاوشلاب ةطبضم
 ةيصوتلا  نلآا  ىتح  لودلا  ضعب  قبطت  لمو  .ضىرلما  ةملاس  لىع
 ءاسنلاو  جمابرلا  يريدم  نم  يرثكلا  لازي  لاو  جلاعلا  اذه  نأشب
 .هب  صىولما  جهنلا  قيبطت  لىع ينلبقم  يرغ  ىرخأ  لود  في لماولحا
 ةطبضلما  ةاشعلما  براجتلا  نم  ينتنثا  ءارجإ  مت  ،2006  ماع  ذنمو
 :لملحا ةترف ءانثأ ”ليتناوكيزابرلا“ ءاود مادختسا نأشب دهاوشلاب
 امأ ،ادنغوأ في ةينوسنلما ايسراهلبلا  ضرم ةحفاكلم اهمادحإ تناك
 لمو .ينبلفلا في ةينابايلا ايسراهلبلا ضرم ةحفاكلم تناكف ىرخلأا
 دلايلما دنع لفطلا نزو لىع ظوحلم رثأ يأ ينتبرجتلا ينتاه في رهظي
 ءاودلا ادبو ،”ليتناوكيزابرلا“ جلاعل لماولحا ءاسنلا يقلتل ةجيتن
 كلت  هبشت  يتلا  ةيبنالجا  راثلآا  نم  دح  ىندأ  ىوس  ببسي  لمو  اًنمآ
 لماولحا يرغ ءاسنلا نم جلاعلا ينقلت نم ىدل ترهظ يتلا راثلآا
 ةدمتسلما ةعجشلما تانايبلا صيخلت دعبو .ةساردلل نعضخ تيلالا
 ةساردو  جلاعلا  ةيلاعف  ىدمب  قلعتي  مايف  ،ينتساردلا  ينتاه  نم
 ةعجارم كلذكو ،ضىرلما ةملاس لىع هيرثأت ىدمو ءاودلا تايكرح
 يتلاو شربلا اله عضخ يتلا تاساردلا نم ةدمتسلما ةملاسلا تانايب
 عيملج  تايصوتل  انلصوت  دقف  ،يبط  ليخادت  ءارجإ  لىإ  جاتتح  لا
 تلاحم نم نيديفتسلما نمض لماولحا ءاسنلا جاردإ بوجوب لودلا
 تابقعلا ديدتح لىع لمعن نحنو .”ليتناوكيزابرلا“ ءاودب جلاعلا
 جردنت يتلا لودلا في – لماولحا ءاسنلا جلاع ليبس في فقت يتلا
 تلاحمو ةيدرفلا تاجلاعلا نم نيديفتسلما نمض ءاسنلا كلت اهيف
 ةهجاوم لبس شقانن كلذكو - ييرهاجم قاطن لىع ءاودلا عيزوت
 .تابقعلا كلت
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Utilisation du praziquantel pour traiter la schistosomiase au cours de la grossesse 
En 2014, on estimait que 40 millions de femmes en âge de procréer 
étaient infectées par Schistosoma haematobium, S. japonicum et/
ou S. mansoni. En 2003 et 2006, l’Organisation mondiale de la Santé 
(OMS) a recommandé qu’un traitement au praziquantel soit offert, 
individuellement ou dans le cadre de campagnes de traitement, à toutes 
les femmes enceintes et allaitantes infectées par le schistosome. En 2006, 
l’OMS a également affirmé la nécessité d’essais contrôlés randomisés 
pour évaluer l’innocuité et l’efficacité de ce traitement. Néanmoins, 
certains pays ne suivent toujours pas la recommandation relative 
au traitement et dans d’autres pays, bon nombre de gestionnaires 
de programme et de femmes enceintes demeurent réticents à 
suivre l’approche recommandée. Depuis 2006, deux essais contrôlés 
randomisés sur l’utilisation du praziquantel au cours de la grossesse ont 
été menés: l’un sur S. mansoni en Ouganda et l’autre sur S. japonicum aux 
Philippines. Dans le cadre de ces essais, le traitement au praziquantel des 
femmes enceintes n’a pas eu d’effet notable sur le poids à la naissance, 
s’est révélé sans danger et a provoqué des effets secondaires minimes, 
similaires à ceux constatés chez les femmes traitées qui n’étaient pas 
enceintes. Ayant résumé les données encourageantes sur l’efficacité, la 
pharmacocinétique et l’innocuité tirées de ces deux essais et examiné 
les données de sécurité provenant d’études non interventionnelles sur 
l’homme, nous recommandons que tous les pays incluent les femmes 
enceintes dans des campagnes de traitement au praziquantel. Nous 
mettons en évidence les obstacles qui empêchent le traitement des 
femmes enceintes – dans des pays les incluant déjà dans des traitements 
individuels et des campagnes d’administration massive de médicaments 
– et décrivons des moyens permettant de surmonter ces obstacles.
Резюме
Применение празиквантела для лечения шистосомоза во время беременности
В 2014 году около 40 миллионов женщин репродуктивного 
возраста были инфицированы Schistosoma haematobium, S. 
japonicum и/или S. mansoni. В 2003 и 2006 годах Всемирная 
организация здравоохранения (ВОЗ) рекомендовала назначать 
всем беременным и кормящим женщинам, инфицированным 
шистосомой, лечение с применением празиквантела как в 
индивидуальном порядке, так и во время массовых кампаний 
по лечению. В 2006 году ВОЗ также заявила о необходимости 
проведения рандомизированных контролируемых испытаний 
для оценки безопасности и эффективности такого лечения. 
Некоторые страны не последовали рекомендации по лечению, 
и многие руководители программ и беременные женщины 
в других странах по-прежнему неохотно придерживаются 
рекомендуемого подхода. С 2006 года было проведено два 
рандомизированных контролируемых исследования применения 
празиквантела во время беременности: одно в Уганде (в нем 
изучали применение этого препарата при инфицировании 
S. mansoni), другое на Филиппинах (при инфицировании S. 
japonicum). В этих исследованиях применение празиквантела у 
беременных женщин не оказывало существенного влияния на 
вес младенцев при рождении, оказалось безопасным и вызывало 
минимальные побочные эффекты, аналогичные тем, которые 
наблюдались при применении этого препарата у небеременных 
пациенток. Исходя из обнадеживающих данных по эффективности, 
фармакокинетике и безопасности, полученных в ходе этих двух 
исследований, и из пересмотренных данных по безопасности 
из неинтервенционных исследований, проведенных на людях, 
рекомендуется всем странам включать беременных женщин в 
кампании по лечению с применением празиквантела. Авторы 
выявляют препятствия для лечения беременных женщин в 
странах, которые уже включили таких женщин в массовые 
кампании по лечению с применением лекарственных препаратов 
или назначают им индивидуальное лечение, и обсуждают пути 
устранения этих препятствий.
Resumen
Praziquantel para el tratamiento de la esquistosomiasis durante el embarazo humano
En 2014, se estima que 40 millones de mujeres en edad reproductiva 
estaban infectadas con Schistosoma haematobium, S. japonicum y/o 
S. mansoni. Tanto en 2003 como en 2006, la Organización Mundial 
de la Salud (OMS) recomendó que todas las mujeres embarazadas 
y lactantes infectadas con esquistosoma recibieran tratamiento, 
con praziquantel, ya fuera individualmente o durante las campañas 
de tratamiento. En 2006, la OMS también informó de la necesidad 
de ensayos aleatorizados controlados para evaluar la seguridad y la 
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eficacia de dicho tratamiento. Algunos países todavía tienen que 
seguir la recomendación sobre el tratamiento y muchos gestores de 
programas y mujeres embarazadas en otros países siguen siendo reacios 
a seguir el enfoque recomendado. Desde 2006, se han llevado a cabo 
dos ensayos aleatorizados controlados sobre el uso de praziquantel 
durante el embarazo: uno contra el S. mansoni en Uganda y el otro 
contra el S. japonicum en Filipinas. En estos ensayos, el tratamiento con 
praziquantel en mujeres embarazadas no tuvo un efecto significativo 
sobre el peso en el momento del nacimiento, pareció seguro y causó 
efectos secundarios mínimos, similares a los observados en sujetos no 
embarazadas tratadas. Después de resumir los alentadores datos sobre la 
eficacia, la farmacocinética y la seguridad de estos dos ensayos y revisar 
los datos de seguridad de los estudios observacionales en humanos, 
recomendamos que todos los países incluyan a mujeres embarazadas 
en las campañas de tratamiento con praziquantel. Identificamos las 
barreras para el tratamiento de mujeres embarazadas, en países que ya 
incluyen a mujeres en los tratamientos individuales y en las campañas 
masivas de administración de medicamentos, y analizamos las formas 
de abordar estas barreras.
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